# US 9,868,743 B2 · Macrocyclic molecules as HCV entry inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,868,743 B2
- Document ID: US9868743B2
- Status: Granted
- Kind: B2
- Application number: 14/765,906
- Filed: 2014-02-04
- Published: 2015-12-24
- Granted: 2018-01-16
- Earliest claimed: 2013-02-07
- Assignees: Bristol-Myers Squibb Company
- Applicants: Bristol-Myers Squibb Company
- Inventors: Tao Wang; Zhongxing Zhang; Eric Gillis; Paul Michael Scola
- Web page: https://patentgrep.com/patent/US9868743B2

## CPC

- C07D 487/08: Bridged systems
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- C07D 498/08: Bridged systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

## Claims

### Claim 1

The compound

### Claim 2 (depends on 1)

A composition comprising the compound of claim 1, and a pharmaceutically acceptable carrier.